Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 3:22 AM
Ignite Modification Date:
2025-12-26 @ 2:00 AM
NCT ID:
NCT03330405
Group ID:
EG000
Title:
Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD
Description:
Participants with locally advanced or metastatic solid tumors were treated with talazoparib 1.0 mg orally once daily (QD) in combination with avelumab 800 mg intravenously (IV) every 2 weeks (Q2W) for a maximum of 246.3 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.
Deaths Number Affected:
6
Deaths Number At Risk:
None
Serious Number Affected:
1
Serious Number At Risk:
12
Other Number Affected:
12
Other Number At Risk:
12
Study:
NCT03330405
Results Section:
NCT03330405
Adverse Events Module:
NCT03330405